Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
NCT01714908 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2017-02-07
Summary
Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR) in exon 19 or 21 versus etoposide plus cis-platin with concurrent radiotherapy.
Conditions
Interventions
- OTHER
-
Erlotinib w Concurrent Radiotherapy
- OTHER
-
etoposide/cis-platin (EP) w Concurrent Radiotherapy
Etoposide / Cis-platin w Concurrent Radiotherapy
Sponsors & Collaborators
-
Roche Pharma AG
collaborator INDUSTRY -
Jinming Yu
lead OTHER
Principal Investigators
-
Jinming Yu, PhD · Shandong Cancer Hospital and Institute
-
Shenglin Ma, PhD · The First People's Hospital of Hangzhou
-
Conghua Xie, PhD · Zhongnan Hospital
-
Ming Chen, PhD · Zhejiang Cancer Hospital
-
Gang Wu, PhD · Tongji Medical College, Huazhong University of Science and Technology, Wuhan Union Hospital
-
Jianhua Wang, PhD · Henan Cancer Hospital
-
Jiancheng Li, PhD · Fujian Province Cancer Hospital
-
Zhengfei Zhu, PhD · Fudan University
-
You Lu, PhD · West China Hospital, West China School of Medicine, Sichuan University
-
Lvhua Wang, PhD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
Guangying Zhu, PhD · Peking University Cancer Hospital & Institute
-
Tingyi Xia, PhD · Chinese PLA General Hospital
-
Chun Han, PhD · Hebei Medical University Fourth Hospital
-
Guang Li, PhD · First Hospital of China Medical University
-
Zhiyong Yuan, PhD · Tianjin Medical University Cancer Institute and Hospital
-
Qin Lin, PhD · The First Affiliated Hospital of Xiamen University
-
Qibin Song, PhD · Renmin Hospital of Wuhan University
-
Yaping Xu, PhD · Zhejiang Cancer Hospital
-
Bing Lu, PhD · Cancer Hospital of Guizhou Province
-
Baolin Qu, PhD · Chinese PLA General Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-12-14
- Primary Completion
- 2018-08-20
- Completion
- 2018-10-20
Countries
- China
Study Locations
More Related Trials
-
Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC
NCT03074864 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
NCT01217619 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
NCT01410214 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
NCT02006043 ·Status: UNKNOWN ·Phase: PHASE2
-
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
NCT02001896 ·Status: UNKNOWN ·Phase: PHASE3
-
Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
NCT01091376 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
NCT01024413 ·Status: COMPLETED ·Phase: PHASE3
-
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
NCT03766490 ·Status: UNKNOWN ·Phase: NA
-
Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
NCT02066038 ·Status: UNKNOWN ·Phase: PHASE2
-
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers
NCT02098954 ·Status: RECRUITING ·Phase: PHASE2
-
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
NCT01407822 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
NCT02140333 ·Status: UNKNOWN ·Phase: PHASE3
-
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
NCT04687241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
NCT00567359 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT02013219 ·Status: COMPLETED ·Phase: PHASE1
-
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
NCT04455594 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy
NCT01297101 ·Status: TEMPORARILY_NOT_AVAILABLE
-
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
NCT02178397 ·Status: TERMINATED ·Phase: PHASE3
-
Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
NCT03050411 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
NCT05778149 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
NCT01211483 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment
NCT01796288 ·Status: UNKNOWN ·Phase: PHASE2
-
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02064491 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
NCT06300424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2